CanSense

The company develops a non-invasive liquid biopsy that utilizes laser spectroscopy and artificial intelligence to detect early-stage bowel cancer and pre-cancerous polyps. This blood test is designed to replace invasive colonoscopies and complex sample preparations with a label-free assay that does not require costly reagents. The technology aims to provide a cost-effective diagnostic tool for the global healthcare market to improve patient outcomes through early detection.